CClinicalTrials.gg
CompletedNCT04297553Updated Feb 24, 2021

Fresh Versus Freeze-only After CAPA IVM on PCOS Patients

An interventional study of CAPA-Fresh and CAPA-Freeze-only in PCOS, IVM and Embryo Transfer, sponsored by Mỹ Đức Hospital. Completed at 1 site in Vietnam. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2021-02-24.

Sponsored by Mỹ Đức Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 37 Years
Sex
Female
01

Study summary

IVM (in vitro maturation) has been proved to be a more friendly treatment protocol for PCOS (polycystic ovary syndrome) patients compared with conventional controlled ovarian stimulation, with less complications (especially ovarian hyperstimulation syndrome), shorter treatment duration, lower cost, and acceptable pregnancy outcomes.

Read the detailed description

IVM (in vitro maturation) has been proved to be a more friendly treatment protocol for PCOS (polycystic ovary syndrome) patients compared with conventional controlled ovarian stimulation, with less complications (especially ovarian hyperstimulation syndrome), shorter treatment duration, lower cost, and acceptable pregnancy outcomes. CAPA (capacitation) IVM without hCG (human chorionic gonadotropin) priming, has routinely been used at My Duc hospital for nearly 3 years to replace hCG-IVM (with hCG priming) because of absolutely synchronized oocyte maturation stage and better embryo results and better pregnancy outcomes. However, with CAPA IVM, embryos are freezed-only and will be transferred in the next cycles. This process will increase the cost of freezing and thawing embryos, and increase the treatment duration, which complicates the IVM procedure and turns IVM into an unfriendly protocol to PCOS patients. Therefore, our group conducts this study to find out the effectiveness of fresh transfer protocol after CAPA IVM compared with freezing-only CAPA IVM protocol. The fresh transfer protocol for CAPA IVM is applied from previous hCG IVM protocol, with the use of hCG and exogenous estradiol and progesterone, but at different timings.

02

Conditions studied

  • PCOS
  • IVM
  • Embryo Transfer
03

In context

Lead sponsor

Mỹ Đức Hospital is the lead sponsor of 55 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women with high AFC (≥24 Antral Follicles in Both Ovaries), including PCOS plus PCO or high AFC
  • Having indications for ART
  • Having ≤ 2 IVM/IVF attempts
  • Permanent resident in Vietnam
  • Agree to have fresh embryos transfer or freeze-only on day 3
  • Agree to have ≤ 2 embryos transferred
  • Not participating in another IVF study at the same time

Exclusion criteria

Exclusion Criteria:

  • Oocyte donation cycles
  • Pre-implantation genetic diagnosis (PGD) cycles
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    CAPA-Fresh

    Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.

    Procedure: CAPA-Fresh

  • Active comparator
    CAPA-Freeze-only

    Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred

    Procedure: CAPA-Freeze-only

Interventions

  • ProcedureCAPA-Fresh

    Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.

  • ProcedureCAPA-Freeze-only

    Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.

06

What researchers measure

Primary outcomes

  1. Ongoing pregnancy resulting in live birth after the first embryo transfer of the started treatment cycle.

    Live birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twin will be a single count). For the timing of this occur, ongoing pregnancy will be used, conditional on the fact that this ongoing pregnancy results in live birth.

    Time frame: At 24 weeks of gestation

Secondary outcomes

  1. Positive pregnancy test

    Serum human chorionic gonadotropin level greater than 5 mIU/mL

    Time frame: at 2 weeks after the embryo placement after the completion of the first transfer

  2. Clinical pregnancy

    at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity

    Time frame: 5 weeks after embryo placement after the completion of the first transfer

  3. Implantation rate

    as the number of gestational sacs per number of embryos transferred

    Time frame: 3 weeks after embryo transferred after the completion of the first transfer

  4. Ongoing pregnancy

    Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after the completion of the first transfer

    Time frame: At 12 weeks' gestation

  5. Number of embryos on day 3

    Number of embryos on day 3

    Time frame: 5 days after oocytes pick-up

  6. Number of good quality embryo on day 3

    good quality embryos are defined followed Istanbul consensus

    Time frame: 5 days after oocytes pick-up

  7. Time from randomisation to ongoing pregnancy

    Time from randomization to ongoing pregnancy after the completion

    Time frame: 12 weeks of gestation after the completion of the first transfer

  8. Time from randomisation to live birth

    Time from randomization to live birth after the completion

    Time frame: At the time of delivery

  9. Ovarian hyperstimulation syndrome (OHSS)

    Routine assessments for OHSS were performed on day 3 post oocyte retrieval in both groups. At other times, OHSS was evaluated if symptoms were reported by the patient. OHSS was classified using the flow diagram developed by Humaidan and colleagues for use in clinical trial settings

    Time frame: at 03 days after oocytes pick-up and 14 days after embryo transfer

  10. Ectopic pregnancy

    a pregnancy in which implantation takes place outside the uterine cavity after the completion of the first transfer

    Time frame: at 12 weeks of gestation after the completion of the first transfer

  11. Miscarriage

    pregnancy loss at \< 24 weeks

    Time frame: at 24 weeks of gestation after the completion of the first transfer

  12. Hypertensive disorders of pregnancy

    Pregnancy-induced hypertension, pre-eclampsia and eclampsia

    Time frame: at 20 weeks of gestation or beyond after the completion of the first transfer

  13. Gestational diabetes mellitus

    using a 75g oral glucose tolerance test

    Time frame: at 24 weeks of gestation after the completion of the first transfer

  14. Preterm delivery

    Multiple definitions, defined as delivery at \<24, \<28, \<32, \<37 completed weeks

    Time frame: at 24, 28, 32 weeks and 37 weeks of gestation after the completion of the first transfer

  15. Multiple pregnancy

    Defined as presence of more than one sac at early pregnancy ultrasound (6-8 weeks gestation)

    Time frame: 5 weeks after embryo placement after the completion of the first transfer

  16. Birth weight

    Weight of singletons and twins

    Time frame: at the time of delivery

  17. Congenital anomaly

    Any congenital anomaly will be included

    Time frame: At birth after the completion of the first transfer

  18. Cost-effectiveness

    Including direct and indirect costs; costs related to complications treatment. Cost data will be collected for a supplementary analysis and will be reported in a separated paper.

    Time frame: Two year after randomization

07

Study locations

1 site
  • Mỹ Đức Hospital
    Ho Chi Minh City, Tan Binh, Vietnam
08

References and documents

Publications

  • Vuong LN, Nguyen LK, Le AH, Pham HH, Ho VN, Le HL, Pham TD, Dang VQ, Phung TH, Smitz J, Ho TM. Fresh embryo transfer versus freeze-only after in vitro maturation with a pre-maturation step in women with high antral follicle count: a randomized controlled pilot study. J Assist Reprod Genet. 2021 Jun;38(6):1293-1302. doi: 10.1007/s10815-021-02180-7. Epub 2021 Apr 6. PubMed 33825118 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04297553
Lead sponsor
Mỹ Đức Hospital
Responsible party
Sponsor
First posted
Mar 5, 2020
Start date
Mar 6, 2020
Primary completion
Aug 18, 2020
Completion
Dec 15, 2020
Last update
Feb 24, 2021

Study contacts

Lan N Vuong, MD, PhD
principal investigator · Mỹ Đức Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion